ADVFN Logo
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

MGNX MacroGenics Inc

14.72
-0.24 (-1.60%)
Mar 28 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 809,041
Bid Price 13.45
Ask Price 14.88
News -
Day High 15.2525

Low
4.29

52 Week Range

High
21.88

Day Low 14.27
Company Name Stock Ticker Symbol Market Type
MacroGenics Inc MGNX NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.24 -1.60% 14.72 20:00:00
Open Price Low Price High Price Close Price Prev Close
14.74 14.27 15.2525 14.72 14.96
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
10,185 809,041 $ 14.86 $ 12,020,734 - 4.29 - 21.88
Last Trade Time Type Quantity Stock Price Currency
19:52:20 10 $ 14.72 USD

MacroGenics Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
919M 62.43M - 151.94M -119.76M -1.92 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

MacroGenics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No MGNX Message Board. Create One! See More Posts on MGNX Message Board See More Message Board Posts

Historical MGNX Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week15.6416.1814.0814.71870,622-0.92-5.88%
1 Month17.8421.8814.0817.481,891,036-3.12-17.49%
3 Months10.0421.889.4516.051,452,6544.6846.61%
6 Months4.7121.884.2912.901,027,21510.01212.53%
1 Year6.7621.884.2910.55754,8307.96117.75%
3 Years32.6636.48042.1311.27771,374-17.94-54.93%
5 Years18.5436.48042.1315.28831,250-3.82-20.60%

MacroGenics Description

Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. The company's strategy includes leveraging partnerships with a therapeutic focus geared toward developing a broad portfolio of pipeline candidates. The company also targets autoimmune disorders and infectious diseases. The company's intellectual property is characterized by its patent use to protect the composition of its product candidates and the technology used to create them.

Your Recent History

Delayed Upgrade Clock